Adherence to oral anticancer chemotherapy: What influences patients’ over or non-adherence? Analysis of the OCTO study through quantitative–qualitative methods

BMC Research Notes

Franck Chauvin⁶  Véronique Trillet-Lenoir⁴  Catherine Rioufol³  Michel Tod¹  Gilles Freyer⁴  Pascal Girard¹  Jérôme Guitton⁵  Florence Ranchon³  Benoit You⁴  Olivier Colomban¹  Chloé Hamant²  Véronique Regnier²  Fabien Tinquaut²  Emilie Henin¹  Aurélie Bourmaud² 

[1] EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France;Public Health Department, Hygée Centre, Lucien Neuwirth Cancer Institut, Inserm, CIC1408, 108 bis avenue A. Raimond, Saint Priest en Jarez, 42 270, France;Oncologic Pharmaceutical Department, Lyon-Sud University Teaching Hospital, Lyon, France;Medical Oncology Department, Teaching Hospital, Lyon-Sud University, Lyon, France;Pharmacology-Toxicology Laboratory, Hospices Civils de Lyon, South Biology Center, Lyon, France;Jean Monnet University, Saint-Etienne, France

关键词: Quantitative–qualitative mixed method;    Profiles;    Adherence;    Adverse events;    Capecitabine;    Oral chemotherapy;   

Others  :  1231583
DOI  :  10.1186/s13104-015-1231-8

 received in 2014-12-30, accepted in 2015-06-15,  发布年份 2015

【 摘 要 】

Background

Numerous oral anticancer chemotherapies are available. Non-adherence or over-adherence to these chemotherapies can lead to lowered efficacy and increased risk of adverse events. The objective of this study was to identify patients’ adherence profiles using a qualitative–quantitative method.

Methods

A capecitabine treatment was initiated for 38 patients with advanced breast or colorectal cancer. At inclusion, information on patients’ beliefs was reported using a questionnaire. Later, Information on patients’ relation to treatment was obtained from a sub-group during an interview with a sociologist. Questionnaires were analyzed using Multiple Classification Analysis to cluster patients. Treatment adherence was evaluated by an electronic medication event monitoring systems (MEMS caps) and then correlated with patient clusters. Interviews were analyzed to complete and explain results.

Results

38 patients were enrolled between 2008 and 2011 and completed the questionnaire. Twenty had adherence measured with MEMS caps all along treatment. Between 4 and 6 months after inclusion, 16 patients were interviewed. Patient profile B (retired, with a regular life, surrounded by a relative’s attention to drug adherence, with a low educational level) was statistically associated with adequate adherence (p = 0.049). A tendency for lower adherence was observed among more highly educated patients with an irregular, active life (NS). All patients taking capecitabine demonstrated a risk of over-adherence, potentiating side effects.

Conclusions

These encouraging primary results suggest that further studies should be undertaken and that educational programs tailored to patient profiles should be evaluated to enhance adherence for those who need it and to empower all patients to manage treatment side effects.

【 授权许可】

   
2015 Bourmaud et al.

【 图 表 】

Figure1.

Figure2.

【 参考文献 】

• [1]Walter T, Wang L, Chuk K, Ng P, Tannock IF, Krzyzanowska MK: Assessing adherence to oral chemotherapy using different measurement methods: Lessons learned from capecitabine. J Oncol Pharm Pract 2013, 20:249-256.
• [2]Bhattacharya D, Easthall C, Willoughby KA, Small M, Watson S: Capecitabine non-adherence: exploration of magnitude, nature and contributing factors. J Oncol Pharm Pract 2012, 18:333-342.
• [3]Partridge AH, Archer L, Kornblith AB, Gralow J, Grenier D, Perez E, et al.: Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol 2010, 28:2418-2422.
• [4]Uematsu T, Nakashima M, Fujii M, Hamano K, Yasutomi M, Kodaira S, et al.: Measurement of 5-fluorouracil in scalp hair: a possible index of patient compliance with oral adjuvant chemotherapy. Eur J Clin Pharmacol 1996, 50:109-113.
• [5]Macintosh PW, Pond GR, Pond BJ, Leung V, Siu LL: A comparison of patient adherence and preference of packaging method for oral anticancer agents using conventional pill bottles versus daily pill boxes. Eur J Cancer Care (Engl) 2007, 16:380-386.
• [6]Mayer EL, Partridge AH, Harris LN, Gelman RS, Schumer ST, Burstein HJ, et al.: Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat 2009, 117:615-623.
• [7]Simons S, Ringsdorf S, Braun M, Mey UJ, Schwindt PF, Ko YD, et al.: Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care. Support Care Cancer 2011, 19:1009-1018.
• [8]Spoelstra SL, Given BA, Given CW, Grant M, Sikorskii A, You M, et al.: An intervention to improve adherence and management of symptoms for patients prescribed oral chemotherapy agents: an exploratory study. Cancer Nurs 2013, 36:18-28.
• [9]Krolop L, Ko Y-D, Schwindt PF, Schumacher C, Fimmers R, Jaehde U: Adherence management for patients with cancer taking capecitabine: a prospective two-arm cohort study. BMJ Open 2013, 3:7.
• [10]Winterhalder R, Hoesli P, Delmore G, Pederiva S, Bressoud A, Hermann F, et al.: Self-reported compliance with capecitabine: findings from a prospective cohort analysis. Oncology 2011, 80:29-33.
• [11]Decker V, Spoelstra S, Miezo E, Bremer R, You M, Given C, et al.: A pilot study of an automated voice response system and nursing intervention to monitor adherence to oral chemotherapy agents. Cancer Nurs 2009, 32:E20-E29.
• [12]Ruddy K, Mayer E, Partridge A: Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009, 59:56-66.
• [13]Thivat E, Van Praagh I, Belliere A, Mouret-Reynier MA, Kwiatkowski F, Durando X, et al.: Adherence with oral oncologic treatment in cancer patients: interest of an adherence score of all dosing errors. Oncology 2013, 84:67-74.
• [14]Bassan F, Peter F, Houbre B, Brennstuhl MJ, Costantini M, Speyer E, et al.: Adherence to oral antineoplastic agents by cancer patients: definition and literature review. Eur J Cancer Care (Engl) 2014, 23:22-35.
• [15]Weingart SN, Toro J, Spencer J, Duncombe D, Gross A, Bartel S, et al.: Medication errors involving oral chemotherapy. Cancer 2010, 116:2455-2464.
• [16]Regnier Denois V, Poirson J, Nourissat A, Jacquin J-P, Guastalla JP, Chauvin F: Adherence with oral chemotherapy: results from a qualitative study of the behaviour and representations of patients and oncologists. Eur J Cancer Care 2011, 20:520-527.
• [17]Patel K, Foster NR, Farrell A, Le-Lindqwister NA, Mathew J, Costello B, et al.: Oral cancer chemotherapy adherence and adherence assessment tools: a report from North Central Cancer Group Trial N0747 and a systematic review of the literature. J Cancer Educ 2013, 28:770-776.
• [18]Spoelstra SL, Given BA, Given CW, Grant M, Sikorskii A, You M, et al.: Issues related to overadherence to oral chemotherapy or targeted agents. Clin J Oncol Nurs 2013, 17:604-609.
• [19]Who Working Group (1988) Therapeutic Patient Education Continuing Education Programmes for Health Care Providers in the Field of Prevention of Chronic Diseases. WHO Regional Office for Europe, Copenhague
• [20]Hartigan K: Patient education: the cornerstone of successful oral chemotherapy treatment. Clin J Oncol Nurs 2003, 7(6 Suppl):21-24.
• [21]Chau I, Legge S, Fumoleau P: The vital role of education and information in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs 2004, 8(Suppl 1):S41-S53.